Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Roivant reports Phase 2b lupus failure for an FcRn drug

One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not improve symptoms by a ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at endpoints.news →

More in Health & Medicine

More from Wednesday 23 September →